Drug Trial News

RSS

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

GlaxoSmithKline (GSK) announced today that they will soon be commencing the first large-scale clinical trial to assess the efficacy of an experimental ebola vaccine.

23 Jan 2015

Alexza begins Phase 2a study of AZ-002 for ARS-related epilepsy management

Alexza Pharmaceuticals, Inc. announced today that it has initiated a Phase 2a study of AZ-002 (Staccato alprazolam), which is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS).

22 Jan 2015

NCCS launches human clinical trial of new cancer vaccine

The National Cancer Centre Singapore has launched a clinical trial of a new cancer vaccine administered to human patients for the first time in the world. Cancer immunotherapy (the harnessing of the body's defence system to fight the patient's cancer, has emerged as one of the most exciting medical breakthroughs in the past two years.

22 Jan 2015

Neuroptis reports positive results from ML7 pre-clinical trial for treatment of dry eye syndrome

Neuroptis, a company specialized in the development of drugs to treat eye disorders, today announces positive results from a second animal trial of its preservative-free ML7 eye drops. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye syndrome.

22 Jan 2015

Eribulin therapy effective in women with metastatic breast cancer

An international research team, led by Dartmouth's Peter A. Kaufman, MD, published findings today in the Journal of Clinical Oncology demonstrating that, while not superior to capecitabine, eribulin is an active and well-tolerated therapy in women with metastatic breast cancer (MBC) receiving this therapy as a first, second, or third line chemotherapy regimen.

22 Jan 2015

Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

Kinex Pharmaceuticals announced today that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas.

20 Jan 2015

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration has removed the partial clinical hold on the Company's aldoxorubicin clinical trials.

20 Jan 2015

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia.

20 Jan 2015

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC).

16 Jan 2015

Researchers assess the effect of IPT for children with anaemia in malaria endemic regions

Researchers from Tanzania and South Africa, who are part of the Cochrane Infectious Disease Group, hosted at LSTM, have conducted an independent review to assess the effect of intermittent preventive antimalarial treatment (IPT) for children with anaemia living in malaria endemic regions. This is a strategy of giving a treatment dose of antimalarial drugs to children at regular intervals just in case they have become infected.

15 Jan 2015

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.

15 Jan 2015

CAR T-cell therapy enters into Phase I clinical trial

Cancer fighting chimeric antigen receptor (CAR) T cells, developed in the Sentman laboratory of Dartmouth's Norris Cotton Cancer Center, are taking the next step into a Phase I clinical trial beginning early in 2015.

15 Jan 2015

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced.

14 Jan 2015

Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that it has initiated a Phase 1 single ascending dose study of TransCon Treprostinil in healthy volunteers.

14 Jan 2015

$Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies$

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.

13 Jan 2015

U-M researchers identify how amlexanox drug improves metabolism of sugar

Researchers at the University of Michigan have identified how a promising drug in clinical trials for the treatment of obesity and related metabolic disorders improves the metabolism of sugar by generating a new signal between fat cells and the liver.

13 Jan 2015

Sheffield breast cancer patient takes part in new drug research trial

A SHEFFIELD patient has become the first in the world to take part in a new drug research trial aiming to better control secondary breast cancer, or cancer which has spread to other parts of the body including the bones, liver and lungs for longer.

12 Jan 2015

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints.

9 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.

8 Jan 2015

$ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL$

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.

8 Jan 2015

Drug Trial News

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

Alexza begins Phase 2a study of AZ-002 for ARS-related epilepsy management

NCCS launches human clinical trial of new cancer vaccine

Neuroptis reports positive results from ML7 pre-clinical trial for treatment of dry eye syndrome

Eribulin therapy effective in women with metastatic breast cancer

Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

Researchers assess the effect of IPT for children with anaemia in malaria endemic regions

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

CAR T-cell therapy enters into Phase I clinical trial

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

U-M researchers identify how amlexanox drug improves metabolism of sugar

Sheffield breast cancer patient takes part in new drug research trial

Two new ODYSSEY trials meet primary efficacy endpoints

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News